<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767490</url>
  </required_header>
  <id_info>
    <org_study_id>SADI</org_study_id>
    <nct_id>NCT04767490</nct_id>
  </id_info>
  <brief_title>Single Anastomosis Versus Standard Duodenal Switch</brief_title>
  <acronym>SADI</acronym>
  <official_title>Single Anastomosis Versus Standard Duodenal Switch - a Prospective Randomized Single-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric&#xD;
      procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However,&#xD;
      its technical difficulty and increased risk of long-term nutritional deficiencies have been a&#xD;
      major hindrance to its diffusion.&#xD;
&#xD;
      Recently, a &quot; simplified &quot; technique of Duodenal-Switch has been proposed by Sanchez-Pernaute&#xD;
      et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first&#xD;
      duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a&#xD;
      terminal intestinal loop used in standard BPD-DS.&#xD;
&#xD;
      The overall objective of this study is to assess in a prospective randomized blinded trial,&#xD;
      the outcomes of this new procedure, using a comprehensive clinical evaluation and follow-up&#xD;
      method. This could potentially change the clinical practice and surgical approach in our&#xD;
      Institution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric&#xD;
      procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However,&#xD;
      its technical difficulty and increased risk of long-term nutritional deficiencies have been a&#xD;
      major hindrance to its diffusion. Our team, with more than 4000 BPD-DS performed since the&#xD;
      early 1990's, is recognized internationally for its expertise with this specific procedure.&#xD;
&#xD;
      Recently, a &quot; simplified &quot; technique of Duodenal-Switch has been proposed by Sanchez-Pernaute&#xD;
      et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first&#xD;
      duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a&#xD;
      terminal intestinal loop used in standard BPD-DS.&#xD;
&#xD;
      This new procedure, called Single Anastomosis Duodenal Switch has the potential benefit of&#xD;
      decreasing the complexity of the standard BPD-DS by avoiding one of the two intestinal&#xD;
      anastomoses usually needed. This could potentially decrease the rate of peri-operative&#xD;
      complications and increase access to this type of surgery.&#xD;
&#xD;
      However, the length of the common channel (250cm) is more than doubled compared to standard&#xD;
      BPD-DS, which could also change significantly the outcomes of the procedure itself. Indeed,&#xD;
      the length of the common channel conditions the absorption of fat and fat-soluble vitamins.&#xD;
&#xD;
      Currently, the scientific literature regarding this procedure is scarce, with only one author&#xD;
      who published his 2-years outcomes, in a cohort study of 100 patients. In addition, this&#xD;
      report presents major limitations. In example, the length of the omega loop was increased&#xD;
      from 200 to 250cm during the course of the study, in order to decrease the rate of protein&#xD;
      deficiency and reoperation for malnutrition. This and other limitations make it hard to&#xD;
      assess the actual results of the technique.&#xD;
&#xD;
      The overall objective of this study is to assess in a stronger study design (i.e. a&#xD;
      prospective randomized single blinded trial), the outcomes of this new procedure, using a&#xD;
      comprehensive clinical evaluation and follow-up method. This could potentially change the&#xD;
      clinical practice and surgical approach in our Institution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excess weight loss</measure>
    <time_frame>2 years</time_frame>
    <description>Excess weight loss at 2 years of follow-up&#xD;
%EWL (Excess weight loss based on an ideal BMI = 25.) and change in BMI as compared to preoperative reference values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of protein deficiency or insufficiency</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Rate of protein deficiency (&lt;35gr/l) or insufficiency (&lt;30gr/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Rate of mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>2 years</time_frame>
    <description>change in BMI at 2 years follow-up as compared to preoperative reference values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>overall and surgery-specific complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure rate of comorbidities</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Remission rate for comorbidities, including T2D, Hypertension, dyslipidemia, sleep apnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of minerals and vitamin deficiencies</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Rate of deficiency and insufficiency in mineral and vitamins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition by bioimpedance measures</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>body fat composition (%) assessed by biompedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>36-item short form survey score from 0 to 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Bariatric Analysis and Reporting Outcomes System score from -7 to 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Laval Questionnaire score from 0 to 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>GastroIntestinal Quality of Life Index from 0 to 144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gatroesophageal reflux symptom</measure>
    <time_frame>from baseline to 60 months</time_frame>
    <description>GastroEsophageal Reflus Disease Score from 0 to 72</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>BPD-DS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SADI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Duodenal Switch</intervention_name>
    <arm_group_label>BPD-DS</arm_group_label>
    <other_name>BPD-DS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Anastomosis Duodenal Switch</intervention_name>
    <arm_group_label>SADI</arm_group_label>
    <other_name>SADI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤60 years&#xD;
&#xD;
          -  Fulfill criteria for bariatric surgery as coined by National Institutes of Health&#xD;
             BMI≥35&#xD;
&#xD;
          -  Give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the following criteria at the time of the baseline visit are&#xD;
        excluded from the study:&#xD;
&#xD;
          -  Presence of the following baseline comorbidities:&#xD;
&#xD;
          -  Inflammatory bowel disease (IBD),&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  History of gastric or duodenal ulcers&#xD;
&#xD;
          -  Preoperative hypoalbuminemia (&lt;35 g/L)&#xD;
&#xD;
          -  History of severe renal, hepatic, cardiac or pulmonary disease&#xD;
&#xD;
          -  Past esophageal, gastric or bariatric surgery&#xD;
&#xD;
          -  Type 1 Diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Evidence of psychological problem that may affect the capacity to understand the&#xD;
             project and to comply with the medical recommendations&#xD;
&#xD;
          -  History of drug use or alcohol abuse in the last 6 months&#xD;
&#xD;
          -  History of gastro-intestinal inflammatory diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Biertho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzy Laroche</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3841</phone_ext>
    <email>suzy_laroche@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélanie Nadeau, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3490</phone_ext>
    <email>melanie.nadeau@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzy Laroche</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3841</phone_ext>
      <email>suzy_laroche@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Laurent Biertho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Marceau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Biron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéfane Lebel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Julien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odette Lescelleur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>André Tchernof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Laurent Biertho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

